As oncology drug development shifts away from maximum tolerated dose–driven paradigms, early design choices now determine whether an active agent ever reaches patients with non–small cell lung cancer (NSCLC). "These are multimillion dollar decisions, and not just that, they're decisions that influence potentially if you're going to find a drug that can help patients," Joshua Reuss, MD, of MedStar Georgetown University Hospital, said during a recent OncLive® Scientific Interchange and Workshop.1 Over a single day, fellows from 4 academic programs worked as drug development teams, advancing 2 simulated assets—a brain-penetrant EGFR × MET bispecific antibody for EGFR-mutant NSCLC and a HER2-directed antibody-drug conjugate (ADC) for HER2-mutant NSCLC—with faculty from academia, industry, biostatistics, and the FDA weighing in at each stage.
Top Takeaways From an OncLive Workshop on Clinical Trial Design
- Faculty described maximum tolerated dose–first escalation and the 3+3 design as obsolete under Project Optimus, with model-based designs and multidose expansion now the default.
- An FDA medical officer said breakthrough therapy decisions are benchmarked to the best available therapy, and that small single-arm datasets rarely clear that bar.
- Patient selection—biomarker enrichment, mandatory biopsies, and eligibility breadth—was framed as the central trade-off between scientific precision and accrual.
How has Project Optimus changed early-phase dose selection?
Cody Chiuzan, PhD, of Northwell Health, said the 3+3 design has effectively disappeared from protocol review. "In the last two years, not one single protocol has used the 3+3," she said, citing model-based and model-assisted designs as the new standard. Because efficacy often plateaus with novel agents while toxicity continues to rise, Chiuzan advocated designs that model safety and efficacy jointly to identify an optimal dose rather than the maximum tolerated dose. Backfill and expansion cohorts, she added, are pushing phase 1 trials into the hundreds of patients.
Parth Desai, MD, MBBS, of Fox Chase Cancer Center, said carrying several doses into expansion typically requires roughly 20 to 30 patients per arm. He pointed to tarlatamab (Imdelltra), for which the phase 2 DeLLphi-301 trial (NCT05060016) evaluated 10-mg and 100-mg doses; the objective response rate (ORR) was 40% with the 10-mg dose vs 32% with the 100-mg dose, and the lower dose moved forward.2 The FDA finalized its guidance on oncology dosage optimization in August 2024.3
What evidence does the FDA need to see from early-phase trials?
Geetika Srivastava, MD, MSPH, a medical officer in gastrointestinal oncology at the FDA, walked fellows through the 30-day investigational new drug review clock. "If you don't hear from the FDA in 30 days, that is good news," she said. Whereas the bar for fast track designation is low, she said, breakthrough therapy designation is measured against the best available therapy. "We are not going for the lowest common denominator there," Srivastava said, noting that ORR data from approximately 10 patients with wide CIs generally fall short. Asked by Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, how "substantial improvement" is defined without a comparator, she acknowledged internal debate: "Sometimes the room is literally half and half split…A slam dunk drug, we will get it."